Connect with us


GSK and Sanofi: another COVID-19 vaccine in the testing phase

The group of projects that are in the most advanced stage of testing to find the coronavirus vaccine is joined by the vaccine developed by the partnership between the French pharma company Sanofi and the British GSK, which has just entered clinical studies in the United States. There are currently 176 potential vaccines against the COVID-19 pandemic in development, according to WHO.



This picture show a person doing some medical tests.

Although in Argentina the pharmaceutical companies that are currently in the spotlight are the British company AstraZeneca and the American company Pfizer, these are not the only pharmaceutical giants that are working hard on bringing a vaccine against COVID-19 to the global market.

Two other major players that are working in this crucial sector are the France-based Sanofi and the UK-based GSK, two of the world’s biggest players in immunization. The two pharma giants have recently started clinical studies for their potential vaccine against COVID-19 in the United States. 

The Born2Invest mobile app makes it easy for you to keep informed, to intuitively move from story to story, and from section to section. Our clean design lets you read articles without clutter, and use the app with no limits on how many articles you can view. Our companion app is a fast and easy way to check the latest business headlines. Be the first to find when a vaccine against the new coronavirus will be released on the market with the Born2Invest mobile app.

The collaboration with Sanofi is one of Glaxo’s seven ventures 

The British company decided to provide its system of adjuvants to other projects, including those carried out by the Chinese biotech company Clover Pharmaceuticals and the Canadian laboratory Medicago.

According to official statements from the companies, early stage clinical trials were launched in 11 different locations and the aim is to have the first results by the end of this year. If all goes well, it could be possible to enter the last stage of the clinical trials before the end of 2020. 

The French-British candidate vaccine combines the technology Sanofi uses to manufacture its influenza vaccines with Glaxo’s special adjuvants. The project has funding available of up to $2.1 billion under Operation Warp Speed, which was launched by the government of the United States. If successful, the effort aims to manufacture and distribute one billion doses by 2021.

Both companies, in turn, are involved in other vaccines against the new coronavirus. GSK provided its adjuvant systems to six other projects, including collaborations with Clover and Medicago. For its part, Sanofi has a potential mRNA vaccine in development with the American Translate Bio, which is still in the preclinical stage.

In the global race, Sanofi and GSK would appear to be running a few months behind AZ, Pfizer, Moderna and the Chinese CanSino and SinoVac, who have already begun Phase III studies. However, John Shiver, Sanofi’s vice president of vaccine R&D, said they can still catch up with their competitors thanks to  the French company’s experience with “very similar viruses.”

Shiver also said that many clinical trials so far have recruited mostly white people. Meanwhile, Sanofi and GSK are going to select a “tremendous diversity” of participants in the clinical trials, across multiple countries for their final research stage in December.

According to the latest update from the World Health Organization, released Thursday, September 3rd, there are currently 176 potential COVID-19 vaccines in development, of which 34 are currently in clinical trials.


(Featured image by Martin Lopez via Pexels)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Angelique Moss is a London-based entrepreneur, writer, and traveller. The world of business, finance, and technology, is her preferred cup of tea. She also writes about the developments and discussions on health, art, luxury and media. A top writer for several Medium publications, she has published hundreds of widely read articles on investing, stocks, global markets, cannabis, and technology for multiple platforms. She is also interested in culture, history, and social affairs.